Clinical Trial Detail

NCT ID NCT04298918
Title A Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

Her2-receptor positive breast cancer

Therapies

Ado-trastuzumab emtansine + Venetoclax

Ado-trastuzumab emtansine

Age Groups: senior adult

Additional content available in CKB BOOST